1-Aryl-3-[4-(thieno[3,2-<i>d</i>]pyrimidin-4-yloxy)phenyl]ureas  as VEGFR-2 Tyrosine Kinase Inhibitors: Synthesis, Biological Evaluation, and Molecular Modelling Studies

<table>Competitive inhibitors of VEGFR-2 in clinical use against several cancers: sunitinib (Sutent, C. P. Pharmaceuticals International, NY, USA), soranefib (Nexavar, Bayer, Germany), axitinib (Inlyta, Pfizer), and pazopanib (Votrient, GlaxoSmithKline).</table>

BioMed Research International

fig1

Figure 1

Figure 1: 1-Aryl-3-[4-(thieno[3,2-<i>d</i>]pyrimidin-4-yloxy)phenyl]ureas  as VEGFR-2 Tyrosine Kinase Inhibitors: Synthesis, Biological Evaluation, and Molecular Modelling Studies 

Figure 1 | 1-Aryl-3-[4-(thieno[3,2-d]pyrimidin-4-yloxy)phenyl]ureas  as VEGFR-2 Tyrosine Kinase Inhibitors: Synthesis, Biological Evaluation, and Molecular Modelling Studies 